We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
Read MoreHide Full Article
Shares of Galectin Therapeutics, Inc. (GALT - Free Report) rallied 14.5% following the company’s release of positive preliminary results from a cohort 3 of a phase Ib study on its pipeline candidate GR-MD-02 in combination with Merck’s (MRK - Free Report) Keytruda. The candidate is currently being evaluated for the treatment of metastatic melanoma in patients whose disease progressed during or after receiving Keytruda as a monotherapy.
So far this year, shares of Galectin Therapeutics have skyrocketed 107.5% compared with the industry’s increase of 4%.
GR-MD-02 is a carbohydrate-based drug candidate inhibiting the galectin-3 protein, directly involved in multiple fatty liver disease plus fibrotic and other malignant diseases.
The phase Ib study is being conducted by the Providence Cancer Institute under principal investigator Brendan D. Curti, M.D., director, Providence Melanoma Program. The objective of the study is to develop a safe dose of GR-MD-02 and measure the response rate in combination with Keytruda. The study demonstrated encouraging results in objective response rate (ORR) and the disease control rate (DCR) for patients with metastatic melanoma.
The evaluation observed the ORR to be 50% in (n=7/14) patients with significant reduction in frequency of suppressive myeloid-derived suppressor cells while the DCR was 64% (n=9/14). The published ORR for Keytruda as a monotherapy in advanced melanoma ranges between 21% and 39%. Moreover, the combination therapy was well tolerated and it delivered a fewer adverse side effects compared with Keytruda alone.
Additionally, the study enrolled 14 patients with metastatic melanoma of which, six patients were diagnosed with head and neck cancer. The observed ORR and DCR were 33% and 67%, respectively, in head and neck cancer. Galectin Therapeutics will continue to collaborate with the Providence Cancer Institute to determine the prospects of GR-MD-02 in immunotherapy combination study.
Notably, Keytruda is the first anti-PD-1 therapy to gain an FDA approval and is now already approved across eight different tumor types in the United States. The drug is continuously growing and expanding into new indications and markets globally.
Galectin Therapeutics currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the same sector are Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and BioSpecifics Technologies Corp. , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Pacira’s earnings estimates have moved 86.2% north for 2018 and 9.9% for 2019 over the past 60 days. The stock has rallied 13.9% year to date.
BioSpecifics’ earnings estimates have been revised 9.1% upward for 2018 and 11.7% for 2019 over the past 60 days. The stock has surged 33.3% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
Shares of Galectin Therapeutics, Inc. (GALT - Free Report) rallied 14.5% following the company’s release of positive preliminary results from a cohort 3 of a phase Ib study on its pipeline candidate GR-MD-02 in combination with Merck’s (MRK - Free Report) Keytruda. The candidate is currently being evaluated for the treatment of metastatic melanoma in patients whose disease progressed during or after receiving Keytruda as a monotherapy.
So far this year, shares of Galectin Therapeutics have skyrocketed 107.5% compared with the industry’s increase of 4%.
GR-MD-02 is a carbohydrate-based drug candidate inhibiting the galectin-3 protein, directly involved in multiple fatty liver disease plus fibrotic and other malignant diseases.
The phase Ib study is being conducted by the Providence Cancer Institute under principal investigator Brendan D. Curti, M.D., director, Providence Melanoma Program. The objective of the study is to develop a safe dose of GR-MD-02 and measure the response rate in combination with Keytruda. The study demonstrated encouraging results in objective response rate (ORR) and the disease control rate (DCR) for patients with metastatic melanoma.
The evaluation observed the ORR to be 50% in (n=7/14) patients with significant reduction in frequency of suppressive myeloid-derived suppressor cells while the DCR was 64% (n=9/14). The published ORR for Keytruda as a monotherapy in advanced melanoma ranges between 21% and 39%. Moreover, the combination therapy was well tolerated and it delivered a fewer adverse side effects compared with Keytruda alone.
Additionally, the study enrolled 14 patients with metastatic melanoma of which, six patients were diagnosed with head and neck cancer. The observed ORR and DCR were 33% and 67%, respectively, in head and neck cancer. Galectin Therapeutics will continue to collaborate with the Providence Cancer Institute to determine the prospects of GR-MD-02 in immunotherapy combination study.
Notably, Keytruda is the first anti-PD-1 therapy to gain an FDA approval and is now already approved across eight different tumor types in the United States. The drug is continuously growing and expanding into new indications and markets globally.
Galectin Therapeutics Inc. Price and Consensus
Galectin Therapeutics Inc. Price and Consensus | Galectin Therapeutics Inc. Quote
Zacks Rank & Stocks to Consider
Galectin Therapeutics currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the same sector are Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and BioSpecifics Technologies Corp. , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Pacira’s earnings estimates have moved 86.2% north for 2018 and 9.9% for 2019 over the past 60 days. The stock has rallied 13.9% year to date.
BioSpecifics’ earnings estimates have been revised 9.1% upward for 2018 and 11.7% for 2019 over the past 60 days. The stock has surged 33.3% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>